The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; ##STR00001##
Wherein R.sup.1, R.sup.3-R.sup.6, X.sup.2 and X.sup.3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; ##STR00001##
Wherein R.sup.1, R.sup.3-R.sup.6, X.sup.2 and X.sup.3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

A method for preventing or treating an arrhythmia including administering an effective amount of hydrogen to a patient in need thereof.

A method for minimizing tachycardia in a subject treated for pain and experiencing tachycardia after being treated with the compound having the structure:

##STR00001##

An effective amount of the compound is administered to a subject, where the effective amount treats pain and minimizes tachycardia in said subject experiencing tachycardia after being administered said compound.

A method for minimizing tachycardia in a subject treated for pain and experiencing tachycardia after being treated with the compound having the structure:

##STR00001##

An effective amount of the compound is administered to a subject, where the effective amount treats pain and minimizes tachycardia in said subject experiencing tachycardia after being administered said compound.

Described herein is a method for forming multi-layer drug dosage forms having at least two layers. In the method, a first formulation comprising a non-gelling matrix forming agent and having a first density is dosed into a preformed mold. A second formulation comprising a non-gelling matrix former and having a second density not equal to the first density is subsequently dosed into the preformed mold. Then, the combination of the formulations dosed into the mold is freeze dried to form the multi-layer dosage form having at least two layers. The use of a density difference between the first and second formulations ensures formation of a product with two distinct layers.

Provided herein is a method for diagnosing and treating a subject at risk for atrial fibrillation (AF) or related health conditions, the method including: collecting one or more physiological signals from the subject in a sleep state or an awake state; extracting time series data from the one or more physiological signals; performing dynamic analyses of the time series data using artificial intelligence, wherein the artificial intelligence calculates a series of dynamic measurements, said dynamic measurements being indicative of a probability of an onset of an abnormal atrial rhythm; providing an integrated personalized risk score including the dynamic measurements, wherein the integrated personalized risk score is indicative of a probability of an onset of AF in the subject; diagnosing the subject as being at risk for AF when the integrated personalized risk score exceeds a threshold value, wherein the threshold value is calculated by the artificial intelligence based on a library of stored data; and treating the diagnosed subject with an effective therapy to prevent or treat AF or AF-related health conditions.

Provided herein is a method for diagnosing and treating a subject at risk for atrial fibrillation (AF) or related health conditions, the method including: collecting one or more physiological signals from the subject in a sleep state or an awake state; extracting time series data from the one or more physiological signals; performing dynamic analyses of the time series data using artificial intelligence, wherein the artificial intelligence calculates a series of dynamic measurements, said dynamic measurements being indicative of a probability of an onset of an abnormal atrial rhythm; providing an integrated personalized risk score including the dynamic measurements, wherein the integrated personalized risk score is indicative of a probability of an onset of AF in the subject; diagnosing the subject as being at risk for AF when the integrated personalized risk score exceeds a threshold value, wherein the threshold value is calculated by the artificial intelligence based on a library of stored data; and treating the diagnosed subject with an effective therapy to prevent or treat AF or AF-related health conditions.

Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.

Methods for treating obstructive hypertrophic cardiomyopathy are described herein. The treatment methods include the administration of a cardiac myosin inhibitor (CK-3773274, also referred to as CK-274 or aficamten) and may include titrating an administrated daily dose based on one or more components of an echocardiogram. The daily dose may be increased, maintained, decreased, or terminated, based on the echocardiogram.